8-K
filed January 10, 2024, 6:59 PM ET
ticker DNA
CIK 0001830214
earnings
confidence high
sentiment positive
materiality 0.60
Ginkgo Bioworks expects to meet 2023 revenue guidance of $250-260M; cash nearly $950M
Ginkgo Bioworks Holdings, Inc.
2023-FY EPS reported
-$0.46
revenue$251,455,000
- Preliminary cell engineering revenue $145-150M, biosecurity up to $110M, total revenue $250-260M.
- New Cell Programs added expected within 80-85 range, meeting prior guidance.
- Biopharma partnerships with Pfizer, Novo Nordisk, Merck, Boehringer Ingelheim; aggregate potential over $1.2B milestones.
- Ended 2023 with nearly $950M cash and cash equivalents; strong balance sheet.
- Full year 2023 financial results to be reported in February 2024.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).
- Period
- for the year ended December 31, 2023
- Guidance
- reaffirmed
- Result
- preliminary results
Exact text from the filing
Ginkgo continues to expect Total revenue of $250 – $260 million in 2023
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).
- Period
- for the year ended December 31, 2023
- Guidance
- reaffirmed
- Result
- preliminary results
Exact text from the filing
Preliminary unaudited Cell Engineering revenue is expected to be within the previously disclosed guidance range of $145 – $150 million in 2023
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).
- Period
- for the year ended December 31, 2023
- Guidance
- reaffirmed
- Result
- preliminary results
Exact text from the filing
Preliminary unaudited Biosecurity revenue is expected to be in line with the previously disclosed guidance of up to $110 million in 2023
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).
- Period
- for the year ended December 31, 2023
- Guidance
- reaffirmed
- Result
- preliminary results
Exact text from the filing
New Cell Programs are expected to be within the previously disclosed guidance range of 80-85 new Cell Programs added to the platform in 2023
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.